



ADVIK LABORATORIES LIMITED

ALL/BSE-ASE/UFR-1/20-21

Dated: 09th September, 2020

To,
The Manager (Listing),
BSE Limited,
1st Floor, P.J. Towers,
Dalal Street, Mumbai - 400001

Sub: Outcome of the Board Meeting and Submission of Un-audited Financial Results for the quarter ended 30th June, 2020 as required u/r 33 of the SEBI (LODR) Regulations, 2015.

Ref: BSE Scrip Code 531686; ASE Scrip Code- 01638 (ADVIK LABO)

Dear Sir,

This is to inform you that pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, the Board of Directors of the Company in its meeting held on Wednesday, 09th September, 2020 at the corporate office of the company at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi - 110001 and concluded just now has, inter-alia, transacted the following businesses:

1. Considered and Approved the Standalone Un-audited Financial Results of the Company for the quarter ended 30th June, 2020.
2. Considered and Approved the Limited Review Report for the Un-audited Financial Results of the Company for the quarter ended 30th June, 2020.

Further, it is hereby informed that the Hon'ble ROC - NCT of Delhi & Haryana vide its Order No ROC/Delhi/AGM Ext./2020/11538 dated 08.09.2020, has allowed the general extension of time for a period of three months to hold the AGM for the financial year ended on 31.03.2020 upto 31.12.2020. The Board has also considered the aforesaid Order and has decided to avail the exemption granted by Hon'ble ROC- NCT of Delhi & Haryana.

We, therefore, hereby further inform you that as per the above order issued by the Hon'ble ROC - NCT of Delhi & Haryana, the Company shall convene its AGM for the financial year ended March 31, 2020 within such extended time, i.e. on or before December 31, 2020 and the date of AGM shall be intimated to the Exchange in due course.



Cont.....2

CIN No. : L74899HR1994PLC038300

Corporate Office : 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi - 110001

Phones : 011-42424884, 43571040-45, Fax : 011-43571047

Regd. Office & Factory : 138, ROZ-Ka Meo, Industrial Area, Sohna - 122103 (Distt. Mewat), Haryana

Phones : 0124-2362471 E-mail : mail@advikindia.com Website : www.advikindia.com

::2 ::

Kindly treat this information as information submitted under Regulation 30 of SEBI (LODR) Regulations, 2015 also.

Further, pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, a copy of the aforesaid Un-audited Financial Results for the quarter ended 30th June, 2020 alongwith Limited Review Report is enclosed herewith for your kind perusal.

Kindly take the aforesaid information in your records.

Thanking you.

Yours Truly,

For Advik Laboratories Limited



(Peeyush Kumar Aggarwal)

Managing Director

DIN: 00090423

Encl: As above

CC:

The Manager (Listing)

Ahmedabad Stock Exchange Limited

1st Floor, Kamdhenu Complex

Opp. Sahajanand College,

Panjara Pole, Ambawadi, Ahmedabad - 380015

ADVIK LABORATORIES LIMITED

Regd. Off. :138, Roz Ka Meo Industrial Area, Sohna, Distt. Mewat Haryana - 122103

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2020

CIN : L74899HR1994PLC038300

Sr No	Particulars	(Rs in Lacs except EPS)			
		Quarter ended			Year Ended
		30-Jun-20 (Unaudited)	31-Mar-20 (Audited)	30-Jun-19 (Unaudited)	31-Mar-20 (Audited)
1	Income from Operation				
	(a) Net Sales/Revenue from Operations	-	-	-	-
	(b) Other Operating Income	-	-	0.44	0.44
	(c) Other Income	-	0.10	0.20	1.06
	Total Income	-	0.10	0.64	1.50
2	Expenses				
	a) Cost of Materials consumed	-	0.08	-	0.08
	b) Purchase of Stock-in-trade	-	-	-	-
	c) Changes in Inventory of Finished goods, Work-in-progress and Stock-in-trade	-	-	-	-
	d) Employee Benefits Expenses	9.65	12.54	10.61	45.05
	e) Finance Costs	0.01	(0.08)	0.01	0.02
	f) Depreciation and Amortisation expense	14.16	13.33	14.64	57.26
	g) Other expenses	4.40	10.12	5.17	22.74
	Total Expenses	28.22	35.99	30.43	125.15
3	Profit/(Loss) before Exceptional items and tax (1-2)	(28.22)	(35.89)	(29.79)	(123.65)
4	Exceptional Items	-	-	-	-
5	Profit/(Loss) before tax (3 + 4)	(28.22)	(35.89)	(29.79)	(123.65)
6	Tax Expenses				
	- Current tax	-	-	-	-
	- Deferred tax	(2.03)	(0.16)	(2.27)	(6.96)
	Total Tax Expenses	(2.03)	(0.16)	(2.27)	(6.96)
7	Profit/(Loss) for the period (5-6)	(26.19)	(35.73)	(27.52)	(116.69)
8	Other Comprehensive Incomes Actuarial Gain/(-)loss on Defined Benefit plan	0.08	(0.71)	0.33	0.28
9	Total Comprehensive Income for the period (7+8)	(26.11)	(36.44)	(27.19)	(116.41)
10	Paid-up equity share capital (face value of Rs 10/- per share)	1,911.14	1,911.14	1,911.14	1,911.14
11	Earning per share (EPS) of Rs 10/- each (not annualized)				
	(1) Basic	(0.14)	(0.19)	(0.14)	(0.61)
	(2) Diluted	(0.14)	(0.19)	(0.14)	(0.61)

NOTES:-

1	The above Financial Results for the quarter ended June 30, 2020 has been reviewed by the Audit Committee and thereafter approved by the Board of Directors & taken on record at its meeting held on September 09, 2020. A Limited review of the same has been carried out by the Statutory Auditors.
2	The Company operates in a single segment viz pharmaceuticals formulations and the results pertain to a single segment in accordance with IND AS 108-Operating Segment.
3	The format for un-audited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular dated July 5, 2016. IND AS and Schedule III (Division II) to the Companies Act, 2013 applicable to the companies that are required to comply with IND AS
4	In the absence of any orders during the quarter under review, there is a decline in the operating activities of the company. The company is trying to find the prospective buyers & believes that the new deals would be finalized soon.
5	The Figures for the quarter ended March 31, 2020 represents the balancing figures between the audited figures for the year ended 31st March, 2020 and the published year to date figures for the 9 months ended December 31, 2019.



	Auditor's Observation:-
6	<p>a) Due to default in payments of bank loans, the company's accounts have been classified as Non-Performing Assets (NPA) by the bank. Indian Overseas Bank has not charged interest on Cash credit & Term Loan Limits. During the period under review no provision has been made for such interest in the books of account of the company and to that extent bank's loan liability and total loss is understated by Rs. 773.59 lacs plus penal charges that the bank may charge. The amount disclosed in the Financial Statements is subject to confirmation adjustments, if any.</p> <p>b) The company had recorded the cost of the investment at the face value of the equity shares issued and had not determined the fair value as required by IND AS. In the absence of the fair value of the securities acquired we are unable to express an opinion on the value of the investment recorded.</p> <p>c) The stock of raw material and work in progress has been valued at cost price. In the current quarter there has been no production, it may have impact on profitability to the extent of its cost less realizable amount if any.</p>
	Our explanation to Auditor's Observation:-
7	<p>a. The Company's accounts had become Non-Performing Assets (NPA) with Indian Overseas Bank (IOB) and due to this reason, IOB has stopped charging interest from the company on its outstanding debts. In view of the above, the company has not charged to statement of Profit & Loss account Interest expenses of Rs. 47.13 Lacs and related penal interest & other charges, if any, for the reported period, in respect of delay of repayments of borrowings from the bank. Further liability for interest expenses of Rs. 726.46 lacs till 31/03/2020 has not been accounted for. The company has made necessary efforts to reach One Time Settlement with IOB & had sent the One Time Settlement proposal with IOB which has been approved by the Bank. As per the terms of the aforesaid One Time Settlement, the company was supposed to clear its outstanding debt by 30th September 2019. However, due to the paucity of funds, the company was unable to clear the debts of IOB. At present, the company is trying to arrange the necessary funds to settle its outstanding debts of IOB and further our company had made a further request to IOB to allow it some more time in order to enable it to settle its outstanding debts as per the terms of aforesaid OTS and the same was under consideration at the end of IOB. However, due to the impact of Corona Virus and the sudden lockdown imposed by both the Central and State Governments in the wake of COVID-19 pandemic, the Company had to suspend its operations, which has adversely impacted its business. Moreover, the labour available with the company also moved to its hometown and all the other employees were unable to attend the office due to the lockdown imposed by the Government. In the absence of any operations, there is a considerable decline in the revenues generated by the company and the profitability of the company during quarter under review has adversely impacted as no operations were being carried on by the Company. Presently, the company is facing many problems such as manpower shortage, liquidity crunch etc. In the current uncertain situation, Company is facing liquidity crunch to meet its day to day business operation expenses.</p> <p>Further, because of the liquidity crunch being faced by the company due to present scenario, our company is now again in the process of making a fresh request to Indian Overseas Bank to allow it some more time to enable it to settle its outstanding debts of IOB as per the terms of aforesaid OTS.</p> <p>b. The company has misplaced/lost the share certificates of the Investment made by it in unquoted equity shares of other companies during the shifting of its records. Hence these share certificates are not physically held by the company. The Company has sent various request letters to the companies in which it has made investments for issue of duplicate share certificates. However, till date the company has not received any reply from these companies. In order to ensure the compliance of IND AS in true letter and spirits, the company is also trying to ascertain the fair market value of its investments.</p> <p>c. In the absence of any orders in the recent past, there is a decline in the operating activities of the company. Hence, the stock of raw material which remained unused is left with the company and is accordingly, reflected in its books of Accounts. The management of the Company is making necessary efforts to find the perspective buyers and to procure the new orders. The Company's management strongly believes that the new deals would be finalized soon. The unused stock of raw material would be utilized in manufacturing finished goods, once the new orders would be procured by the Company. Therefore, the company has valued its stock of raw material at cost price and not at its realizable amount because the Company intends to carry on its operations in near future and to use the stock of raw materials available with it in manufacturing activities as soon as the company will procure new orders.</p>
8	There is a delay in payment of Annual Listing Fees to the stock exchanges where the shares of the Company are listed. In term of circular bearing no. ISIICOMP/OPS116/2019-2020 dated June 11, 2019 and Notice bearing no. 20190903-37 dated September 03, 2019, action(s) is initiated against the company.
9	The Company is assessing the possible effects that may results from the pandemic COVID-19 on the carrying amount of assets/liabilities. The impact assessment of COVID-19 is a continuing process given its nature and duration. The Company will continue to monitor this aspect for any material changes in future economic conditions
10	Previous year/period figures have been regrouped/arranged, wherever necessary to make them comparable with the current period figure.

For and on behalf of Board of Directors
of Advik Laboratories Ltd.

(Peeyush Kumar Aggarwal)
Chairman
DIN : 00090423



Place: New Delhi
Date: 09.09.2020



RMA & ASSOCIATES LLP

Chartered Accountants
LLPIN: AAI-9419 (ISO 9001:2015)

Address : First Floor, 95, National Park,
Lajpat Nagar IV, New Delhi - 110029
Phone : 011-49097636
Email : carahiv@gmail.com
Website : www.rma-ca.com

Independent Auditors Review Report on Quarterly Unaudited Standalone Financial Results of the company for the quarter ended June, 2020 (Pursuant to the Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015 as amended)

The Board of Directors of
Advik Laboratories Limited

We have reviewed the accompanying statement of unaudited Standalone financial results of M/s Advik Laboratories Limited for the quarter ended on 30th June, 2020 being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosures Requirements) Regulations, 2015, read with SEBI circular CIR/CFD/CMD1/44/2019 dated March 29, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Attention is drawn to the following points:

- Due to default in payments of bank loans, the company's accounts have been classified as Non-Performing Assets (NPA) by the bank. Indian Overseas Bank has not charged interest on Cash credit & Term Loan Limits. During the period under review no provision has been made for such interest in the books of account of the company and to that extent bank's loan liability and total loss is understated by Rs. 773.59 lacs plus penal charges that the bank may charge. The amount disclosed in the Financial Statements is subject to confirmation, reconciliation and adjustments, if any.
- The company had recorded the cost of the investment at the face value of the equity shares issued and had not determined the fair value as required by Ind AS. The shares were not made available for physical verification. Hence, we are unable to comment upon the physical existence and express an opinion on the value of investment recorded.
- The stock of raw material and work in progress has been valued at cost price. In the current year there has been no production, it may have impact on profitability to the extent of its cost less realizable amount if any.

For M/s. RMA & Associates LLP
Chartered Accountants
LLPIN: AAI-9419/N500062



(Amit Jain)
Partner

(Membership No. 503109)

UDIN: 20503109AAAABA5856

Place : New Delhi

Date : 09th September, 2020